GlobalData reports companies are in a race to bring alternative obesity treatments to the market, as featured in ET HealthWorld.

In a recent report by GlobalData, it has been highlighted that the obesity drug market in the US is experiencing a significant surge, with 13 new drug launches projected over the next five years. This growth comes in response to the rising obesity rates among US adults, which have increased from 31% in 1999 to 42% in 2020, with a forecast of nearly 50% of US adults being obese by 2030.

The two blockbuster drug launches that have paved the way for this market expansion are Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s Mounjaro (tirzepatide), generating $9.7 billion globally in 2023. These drugs have demonstrated the lucrative potential of the obesity market, leading other companies to develop and commercialize their own obesity treatments.

According to Jasper Morley, a Pharma Analyst at GlobalData, the upcoming years will witness a substantial increase in the number of obesity drug launches, with a peak expected in 2027 and 2028, representing a 333% increase compared to the previous five-year period.

Novo Nordisk is poised to lead this market expansion with six out of the 13 estimated launches, including its lead pipeline drug, Cagrisema (semaglutide + cagrilintide). This drug is currently in Phase III for obesity and is projected to generate $7.4 billion by 2029 in the US.

With the potential for great returns in the obesity drug market, companies are gearing up to capitalize on the growing patient population and the increasing demand for obesity treatments. The future of the US obesity market looks promising, with a myriad of new launches on the horizon.